RxDoctor Payments Data

Vincent Ibelli, MD

Family Medicine · Tappan, NYNPI 1033119599

Payments from drug & device makers

$22,887in general payments, 2019–2025

Across 721 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • GSK$2K
  • AstraZeneca$1K
  • Pfizer$933
  • Novo Nordisk$928
  • Bayer$508
  • plus $5K from 39 others

What the payments were for

  • Speaking & faculty fees$11,40050%
  • Travel & lodging$300%
  • Food & beverage$11,41050%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,887 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$507,181
Medicare patients
773
Services billed
6,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$101,993
FarxigaDapagliflozin Propanediol76$92,086
TradjentaLinagliptin50$59,002
RybelsusSemaglutide42$55,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$51,012
MounjaroTirzepatide39$47,042
XareltoRivaroxaban45$45,989
JanuviaSitagliptin Phosphate26$37,692
JanumetSitagliptin Phos/Metformin Hcl37$34,070
JardianceEmpagliflozin21$32,344
LinzessLinaclotide35$27,110
EntrestoSacubitril/Valsartan18$23,790
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$17,694
EdarbiAzilsartan Medoxomil24$13,784
Rosuvastatin Calcium1,040$12,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,425$109,780104 claims
PfizerEliquis$933$101,993116 claims
Boehringer IngelheimTradjenta, Jardiance$407$91,34671 claims
MerckJanuvia, Janumet$198$71,76263 claims
GSKTrelegy Ellipta, Breo Ellipta$1,535$57,80675 claims
Novo NordiskRybelsus$928$55,76342 claims
Lilly USA, LLCMounjaro$452$47,04239 claims
Johnson & JohnsonXarelto$493$45,98945 claims
AbbVieLinzess, Synthroid$13,049$37,994169 claims
NovartisEntresto$317$23,79018 claims
Arbor Pharmaceuticals, Inc.Edarbi$242$13,78424 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$69$8,966462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Tappan

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →